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ABSTRACT
Palmitic acid (PA) induces hepatocyte apoptosis and fuels de novo ceramide 
synthesis in the endoplasmic reticulum (ER). Myristic acid (MA), a free fatty acid 
highly abundant in copra/palmist oils, is a predictor of nonalcoholic steatohepatitis 
(NASH) and stimulates ceramide synthesis. Here we investigated the synergism 
between MA and PA in ceramide synthesis, ER stress, lipotoxicity and NASH. Unlike 
PA, MA is not lipotoxic but potentiated PA-mediated lipoapoptosis, ER stress, 
caspase-3 activation and cytochrome c release in primary mouse hepatocytes 
(PMH). Moreover, MA kinetically sustained PA-induced total ceramide content by 
stimulating dehydroceramide desaturase and switched the ceramide profile from 
decreased to increased ceramide 14:0/ceramide16:0, without changing medium and 
long-chain ceramide species. PMH were more sensitive to equimolar ceramide14:0/
ceramide16:0 exposure, which mimics the outcome of PA plus MA treatment on 
ceramide homeostasis, than to either ceramide alone. Treatment with myriocin 
to inhibit ceramide synthesis and tauroursodeoxycholic acid to prevent ER stress 
ameliorated PA plus MA induced apoptosis, similar to the protection afforded by the 
antioxidant BHA, the pan-caspase inhibitor z-VAD-Fmk and JNK inhibition. Moreover, 
ruthenium red protected PMH against PA and MA-induced cell death. Recapitulating 
in vitro findings, mice fed a diet enriched in PA plus MA exhibited lipodystrophy, 
hepatosplenomegaly, increased liver ceramide content and cholesterol levels, ER 
stress, liver damage, inflammation and fibrosis compared to mice fed diets enriched 
in PA or MA alone. The deleterious effects of PA plus MA-enriched diet were largely 
prevented by in vivo myriocin treatment. These findings indicate a causal link between 
ceramide synthesis and ER stress in lipotoxicity, and imply that the consumption of 
diets enriched in MA and PA can cause NASH associated with lipodystrophy.
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INTRODUCTION
Nonalcoholic steatohepatitis (NASH) is an 
advanced stage of fatty liver disease that can progress 
to cirrhosis and liver cancer. NASH is associated with 
obesity, lipodystrophy and type-2 diabetes. Hepatocyte 
apoptosis is a multifaceted event of relevance for NASH 
[1]. Palmitic acid (PA) is the most abundant saturated fatty 
acid (SFA) found in Western diets and processed foods and 
it is known to cause lipoapoptosis in hepatocytes through 
different mechanisms, including endoplasmic reticulum 
(ER) stress, mitochondrial dysfunction, JNK activation, 
lysosomal membrane permeabilization and death receptor 
5 (DR5) activation [2-9]. Palmitoyl-CoA derived from 
PA is a precursor of ceramide species, a heterogeneous 
family of sphingolipids present in biological membranes 
that define specific microdomains involved in signaling 
cascades [10-12]. De novo ceramide synthesis takes 
place in the ER and begins with the condensation of 
the amino acid L-serine with palmitoyl-CoA to form 
3-ketosphinganine, in a reaction catalyzed by the rate-
limiting enzyme serine palmitoyltransferase (SPT). 
Reduction of 3-ketosphinganine to sphinganine followed 
by acylation with fatty acyl chains of varying lengths by 
ceramide synthases (CerS) generates dihydroceramide [13, 
14]. Finally, dihydroceramide desaturase (DES) creates a 
double trans4-5 bond thereby converting dihydroceramide 
into ceramide. Besides its function in membrane 
biophysics and function, ceramide has been recognized as 
a second messenger involved in multiple cell processes, 
including cell stress and cell death, senescence and 
differentiation, ER stress, autophagy and disruption of 
mitochondrial function [10, 12, 15-17].
Myristic acid (MA) is a SFA found in small amounts 
( < 1% of total free fatty acids, FFAs) in animal tissues. 
However, MA is highly abundant in milk fat (7-12%) 
and, especially, in copra and palmist oils where MA can 
reach up to 23% of total fatty acids [18]. MA has recently 
been identified as a predictor of NASH, as increased 
serum MA levels have been reported in patients with 
NASH compared to subjects with simple steatosis and 
correlated with fibrosis stage [18]. Dietary MA has been 
shown to accumulate in liver and adipose tissue in rats 
[19]. Moreover, in situ lipidomic analysis by cluster TOF-
SIMS imaging revealed the presence of MA and other 
SFA in steatotic areas in patients with fatty livers [20]. 
Furthermore, previous studies reported that the N-terminal 
myristoylation of DES increased DES activity in COS-7 
cells, thereby stimulating ceramide synthesis [21]. Since 
the contribution of ceramide to ER stress caused by PA 
has been poorly characterized and because the interplay 
between PA and MA in hepatocyte lipoapoptosis has 
not been previously examined, the purpose of our study 
was to explore whether MA synergizes with PA to cause 
lipoapoptosis in hepatocytes. Moreover, mice were 
fed a diet enriched in both MA and PA to examine the 
course of NASH progression. Our findings show that 
MA potentiates PA-induced lipoapoptosis in primary 
mouse hepatocytes (PMH) and mice fed a diet enriched 
in MA and PA exhibits lipodystrophy, increased hepatic 
ceramide and cholesterol levels, liver injury, inflammation 
and fibrosis, effects that were prevented by inhibition of 
the novo ceramide synthesis. These results indicate that 
the consumption of diets enriched in MA (copra/palmist 
oils) and PA (western/processed foods) may lead to NASH 
associated with lipodystrophy.
RESULTS
PA plus MA cause mild steatosis and generate 
selective ceramide species
MA is little abundant in mammalian tissues but 
highly enriched in milk fat and, particularly, in copra 
and palmist oils where MA accounts for up to 23% of 
total free fatty acids. To examine the impact of MA in 
modulating the lipotoxic effect of PA, we used MA at mM 
concentration to mimic the exposure resulting from the 
consumption of diets enriched in MA (e.g. copra/palmist 
oils); moreover, to investigate the effect of MA-rich milk 
fat-based diet in diabetic cardiomyopathy, Russo et al 
incubated cardiomyocytes with 1.5 mM MA [22]. We first 
compared the effect of PA, MA and their combination 
PA plus MA (PM) in intracellular lipid content in PMH 
with respect to that caused by the unsaturated fatty acid 
oleic acid (OA). Control treatment (BSA alone) showed 
scarce lipid accumulation in the cytoplasm of PMH as 
evidenced by oil-red staining, whereas treatments with 
PA or MA caused mild steatosis compared to that elicited 
by OA (Figure 1A). Combination of PA with OA (PO) 
resulted in increased macrovesicular steatosis with respect 
to either PA or OA alone, which contrasts with the onset 
induced by the combination of PA plus MA (Figure 1A). 
Determination of triglyceride (TG) levels indicated that 
OA and its combination with PA (PO) promoted more TG 
accumulation than either fatty acid alone (Figure 1B). The 
effect of MA plus OA in oil-red staining and TG levels 
was similar to that caused by PA and OA (not shown).
We next analyzed ceramide levels following FFAs 
exposure. Kinetic analyses of ceramide generation 
indicated that in contrast to the accumulation of TG, OA 
did not increase total ceramide content compared to PA 
or MA alone and especially their combination PA plus 
MA (PM), whose effect in increasing total ceramide mass 
increased over time and peaked after 12 hour of incubation 
(Supplemental Figure 1), indicating the ability of PA plus 
MA to kinetically sustain ceramide generation. In order 
to further analyze the involvement of MA in ceramide 
production, cells were treated with a constant dose of PA 
and increasing doses of MA, and total ceramide levels 
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Figure 1: Effect of PA and MA in TG levels and ceramide species. PMH were incubated with PA, MA or OA and the combination 
PA plus MA (PM) and PA plus OA (PO) at 0.5mM overnigh. PMH were processed for oil-red staining A. and for the determination of TG 
levels at the concentrations indicated B. In some cases, PMH were treated with 0.5mM PA and with increasing MA doses as indicated to 
determine total ceramide levels C. Moreover, lipid extracts were analyzed by mass spectrometry to determine the relative abundance of 
different ceramide species D. Results are the mean±SEM of N = 5-6 individual experiments. *p < 0.05 vs. control and PA-treated PMH. 
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were quantified by HPLC. As seen, total ceramide levels 
augmented with increasing MA concentrations, indicating 
the potentiation of PA-induced ceramide synthesis by MA 
(Figure 1C). 
To characterize the individual ceramide species 
generated in response to PA plus MA in comparison with 
PA, samples were analyzed by mass spectrometry. The 
content of long-chain ceramides (C20-C25) (Supplemental 
Figure 2) as well as medium-chain ceramides (18:0 and 
18:1) (Figure 1D) induced by PA with or without MA did 
not differ significantly, and similar changes were observed 
in glucosylceramides (Supplemental Figure 3). As for 
shorter chain ceramides, PA alone caused a predominant 
increase in ceramide 16:0, which significantly decreased 
by the combination of PA and MA (Figure 1D). Moreover, 
MA alone induced a significant increase in ceramide 14:0 
compared to PA, which further increased (3-4 fold) in the 
presence of PA (PM) (Figure 1D). Thus, the combination 
PA and MA generated ceramide 14:0 and ceramide 16:0 
at equimolar concentration. As expected, treatment of 
hepatocytes with OA barely changed ceramide levels. 
These findings indicate that PA plus MA modestly 
increase TG but enhance ceramide levels whose profile 
switches from decreased ceramide 14:0/16:0 by PA alone 
to increased ceramide 14:0/16:0 by PA plus MA. 
MA exacerbates PA-induced lipoapoptosis
PA is a lipotoxic SFA that targets different 
organelles, including ER and mitochondria mediating 
hepatocyte apoptosis [6, 7]. To address the synergism 
between PA and MA in lipoapoptosis, we used 
equimolar concentrations of both fatty acids at a relevant 
concentration found in western diets (PA) and copra/
palmist oils (MA). Unlike PA, MA alone did not kill PMH 
as indicated by propidium iodide and Hoescht staining 
(Figure 2A). However, the combination of PA plus MA 
significantly increased cell death compared to PA alone 
(Figure 2B). As seen, the lipotoxicity of PA augmented 
with increasing doses of MA (Figure 2C). Moreover, 
while MA did not kill hepatocytes at any concentration, 
0.5mM PA in the presence of MA (0.5mM) (black column 
Figure 2C) killed more hepatocytes than 0.5mM PA alone 
and similar to the degree of cell death caused by 1.0mM 
PA alone (light grey column Figure 2C), indicating a 
synergistic effect of MA in PA-induced lipotoxicity. 
Moreover, cell death determined by the extracellular 
release of glutathione-S-transferase (GST), as described 
in Supplemental Methods, showed similar results as those 
observed by propidium iodide/Hoescht staining. Further, 
caspase 3 activity determined by release of 7-amino-
4-trifluoromethyl coumarin from Ac-DEVD-AMC 
(not shown) confirmed the potentiation of PA-induced 
lipoapoptosis by MA. Consistent with the role of OA in 
increasing TG levels but not ceramide, co-incubation of 
PA with OA (PO) prevented cell death by PA (Figure 2B). 
Cerulenin, a specific fatty acid synthase inhibitor [23], 
did not affect the lipotoxicity of PA plus MA (not shown), 
suggesting that the potentiation of PA-mediated cell death 
by MA was not due to newly synthesized PA.
To further characterize the type of cell death caused 
by PA and MA we analyzed signs of apoptotic cell death, 
including the status of caspase-3 cleavage and cytochrome 
c release. As seen, PA plus MA (PM) increased the 
level of caspase 3 cleavage as well as the processing of 
PARP, a target of active caspase 3, with respect to PA 
alone (Figure 2D). Consistent with these findings, PA 
plus MA enhanced the release of cytochrome c from 
mitochondria to the cytosol (Figure 2E) compared to PA 
alone. As expected from these findings the pan-caspase 
inhibitor z-VAD-Fmk significantly ameliorated PA plus 
MA-induced hepatocellular apoptosis (Figure 2F). In 
line with the switched ceramide profile caused by PA 
plus MA with respect to PA alone, equimolar ceramide 
14:0 and ceramide 16:0, mimicking the combination 
of PA with MA, caused more cell death in PMH than 
either ceramide species separately (Supplemental Figure 
4A). In addition, consistent with previous findings 
[21], MA but not PA dose-dependently stimulated DES 
activity (Supplemental Figure 4B), in line with the 
kinetically sustained generation of total ceramide levels 
(Supplemental Figure 1). These findings underscore that 
MA potentiates PA-induced hepatocyte apoptosis and 
involves the mitochondrial apoptotic pathway.
MA potentiates PA-induced reactive oxygen 
species through de novo ceramide synthesis
Since PA plus MA targeted the mitochondrial 
apoptosis pathway, we next addressed whether the 
combination of these fatty acids induced the generation 
of reactive oxygen species (ROS). As shown, treatment 
with PA alone increased ROS generation determined by 
dichlorofluorescein-diacetate, and this effect was enhanced 
by the combination of PA plus MA (PM) (Figure 3A). 
The presence of the unsaturated fatty acid OA prevented 
PA-induced ROS production (Figure 3A). To examine 
the impact of ROS generation in PA plus MA induced 
lipotoxicity, we examined the effect of the antioxidant 
BHA. The incubation with BHA suppressed PA and PA 
plus MA-mediated ROS overproduction (Figure 3B) 
and protected PMH against PA and PA plus MA-induced 
cell death (Figure 3C). To determine whether ceramide 
synthesis contributed to the oxidative stress caused 
by PA with or without MA, PMH were pretreated with 
myriocin, a specific SPT inhibitor, which prevents de 
novo ceramide synthesis [24]. In line with previous 
findings [24], myriocin inhibited SPT activity by 90% 
based on the conversion of water-soluble [3H]serine to the 
chloroform-soluble product, 3-ketodihydrosphingosine. 
Importantly, myriocin significantly reduced ROS 
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Figure 2: Effect of PA and MA in hepatocyte lipoapoptosis. PMH were treated with PA, MA and combination PA plus MA (PM) 
and cells were examine by phase contrast and staining with propidium iodide (PI) or Hoëscht A. Alternatively, cell death caused by PA and 
MA was determined by trypan blue exclusion to determine percentage of cell death B. and C. In some cases, extracts were processed for 
the determination of PARP processing and caspase 3 cleavage D., as well as cytochrome c release E. The effect of pan-caspase inhibitor 
z-VAD-Fmk (15µM) on PA and PA plus MA (PM) was determined F. The Results are the mean±SEM of N = 6-8 individual experiments. 
*p < 0.05 vs. control and PA-treated PMH. 
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Figure 3: Effect of the antioxidant BHA and the SPT inhibitor myriocin in PA and PA plus MA-induced reactive 
oxygen species and cell death. PMH were treated with PA with or without MA (0.5mM each) for 12 hours. Cell death was then 
evaluated by trypan blue exclusion A. In some cases, cells were incubated with BHA (100µΜ) in the presence of PA and PA plus MA and 
ROS generation by DCF B. and cell death C. were determined. Alternatively, PMH were treated with myriocin (20µΜ) to block de novo 
ceramide synthesis and its effect on ROS generation D. and cell death E. were analyzed. Results are the mean±SEM of N = 5-6 individual 
experiments. *p < 0.05 vs. control and PA-treated PMH. 
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generation and protected against PA plus MA-induced cell 
death in response to PA and PA plus MA (Figure 3D, 3E). 
Silencing SPT by siRNA reproduced the protective effects 
of myriocin on ROS generation and cell death caused by 
PA plus MA (not shown). These findings indicate that 
oxidative stress caused by de novo ceramide synthesis 
contributes to cell death induced by PA plus MA.
MA enhances PA-induced ER stress
ER stress has been involved in the pathogenesis 
of NASH [25, 26]. In addition to its role in restoring 
homeostasis, persistent ER stress induction triggers 
apoptosis. Therefore, we monitored ER stress markers 
in PMH after incubation with PA with or without MA. 
Exposure of hepatocytes to PA with or without MA for 
1-2 hours failed to induce ER stress markers, consistent 
with the lack of early ceramide generation (not shown). 
However, after 6 hours of incubation, PA induced the 
expression of ATF4 (not shown), CHOP and sXBP-1 at the 
mRNA level (Figure 4A, 4B). In line with the mild effect 
in total ceramide levels, MA alone caused a small increase 
in the expression of ER stress markers (Figure 4A, 4B) 
that was not enough to cause cell death (Figure 2B, 2C), 
suggesting a threshold between ceramide generation, 
the induction of ER stress and cell death. However, 
MA potentiated the increase in the ER stress markers 
induced by PA after 12 hr of incubation (Figure 4A, 4B, 
4C), coinciding with the increment of ceramide levels 
(Supp Figure 1). Furthermore, consistent with the ability 
of OA to protect against PA-induced cell death (Figure 
2B), OA reduced PA-mediated induction of ER stress 
markers CHOP and sXBP1 (Figure 4A, 4B); in addition 
OA prevented PA-induced ROS production (Figure 3A). 
These protective effects of OA can be accounted for by its 
capacity to prevent ceramide synthesis and the stimulation 
of TG accumulation (Figure 1B) thus restraining ceramide 
formation. Overall these findings suggest that OA 
protected against PA-induced lipoapoptosis by channeling 
PA for TG synthesis. In addition, confocal microscopy 
analyses indicated the nuclear localization of CHOP in 
response to PA and particularly PA plus MA (Figure 4D). 
To assess whether ER stress contributed to the potentiation 
of the lipotoxicity of PA by MA, we determined the effect 
of chemical chaperones, such as tauroursodeoxycholic 
acid (TUDCA) that prevents ER stress [27]. As seen, 
TUDCA reduced the induction of ER stress markers 
CHOP and sXBP1 caused by PA with or without MA 
(Figure 4E), and protected PMH against PA plus MA-
induced lipotoxicity (Figure 4F). In addition, TUDCA 
treatment reduced ROS generation caused by PA with or 
without MA (Supplemental Figure 5). However, TUDCA 
pretreatment did not abrogate the increase in ceramide 
levels caused by PA with or without MA (not shown). 
In addition, to examine if de novo ceramide generation 
participates in the ER stress caused by PA and MA, we 
determined the effect of SPT inhibition by myriocin. We 
used myriocin to block de novo ceramide synthesis instead 
of genetic inactivation of CerS to avoid compensatory 
ceramide generation, as described recently in CerS2+/- and 
CerS2-/- mice [28, 29]. In line with these data, we observed 
that CerS2+/- PMH treated with PA with or without MA 
exhibited enhanced ceramide and glucosylceramide levels 
and ER stress compared to CerS2+/+ PMH (not shown). 
However, myriocin pretreatment prevented the increase 
in total ceramide production by PA with or without MA 
(Figure 5A), and this outcome resulted in the amelioration 
of ER stress markers CHOP and sXBP1 (Figure 5B, 
5C). Thus, these findings suggest a link between de novo 
ceramide generation and ER stress caused by PA and MA.
Ruthenium red protects against PA and MA-
induced lipoapoptosis
To further explore the mechanism of mitochondrial 
recruitment in the lipoapoptosis induced by PA and 
MA, we tested the effect of ruthenium red (RR). RR is 
a known inhibitor of the mitochondrial Ca2+ uniporter 
[30], which imports Ca2+ into the mitochondrial matrix to 
impact mitochondrial function, including mitochondrial 
permeability transition. In line with previous results in 
hepatocytes [7], RR protected PMH from PA and PA plus 
MA-mediated cell death (Supplementary Figure 4C). 
Overall and consistent with previous findings [7], the 
data of RR along with the ability of TUDCA to prevent 
PA-induced ROS suggest a cross-talk between ER and 
mitochondria in the lipoapoptosis induced by PA, likely 
via Ca2+ uptake into mitochondria by a RR sensitive 
mechanism. 
JNK inhibition protect against PA plus MA-
induced cell death
As JNK activation has been shown to play a critical 
role in PA-mediated lipotoxicity, we next checked the 
efficacy of JNK inhibition by SP600125. As shown, 
SP600125 protected primary hepatocytes against PA with 
or without MA-mediated cell death as well as the expected 
JNK activation (Supplementary Figure 6). Interestingly, 
the effect of SP600125 was not potentiated by BHA and 
TUDCA (not shown), suggesting that JNK activation, 
ROS generation and ER stress converge in a common 
pathway.
Chronic consumption of PA plus MA-enriched 
diet results in lipodystrophy and progressive liver 
disease
To address the relevance of the findings in PMH, 
mice were fed custom-made diets in which fat was derived 
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Figure 4: ER stress induction by PA and PA plus MA and the effect of TUDCA. PMH were treated with PA and PA plus 
MA (0.5mM) to determine the expression of ER stress markers at 6 hr A. and 12 hr B. post treatment. sXBP-1 levels from PMH after 
incubation with PA and PA plus MA (PM) for 12 hours C. Confocal imaging of CHOP and nuclei of PMH treated with PA and PA plus MA 
(PM). Nuclei were visualized after staining with Hoëscht. In some cases, PMH were treated in the absence or presence of TUDCA (25µM) 
to determine its impact on CHOP and sXBP-1 expression E. as well as cell death F. Results are the mean±SEM of N = 5-7 individual 
experiments. *p < 0.05 vs. control and PA-treated PMH. 
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from PA, MA or their combination (PM) for 6 months. 
In all cases, required amount of essential fatty acids was 
ensured by supplementing diets with C18:3 n-3 [19]. A 
singularity of these custom-made diets compared to high 
fat diets typically used in obesity studies is that mice 
did not become obese in any condition (Figure 6A) and 
exhibited reduced epididymal adipose tissue that was 
especially pronounced with the diet enriched in PA plus 
MA, indicating the induction of nutritional lipodystrophy. 
Moreover, mice fed the combination PA plus MA diet 
displayed hepatosplenomegaly (Figure 6A). Blood serum 
analyses showed increased AST and ALT levels in mice 
fed PA diet that was enhanced by the combination PA 
plus MA diet indicating increased liver damage (Figure 
6B). H&E analyses showed normal appearance in mice 
fed the diet enriched in MA compared to mice fed diet 
enriched in PA, which exhibited parenchymal architecture 
disorganization; these effects were exacerbated in mice 
fed PA plus MA and were accompanied by inflammatory 
cell infiltration (Figure 6B) and myeloperoxidase staining. 
Chronic feeding the PA-enriched diet caused liver 
fibrosis as indicated by Sirius red staining and increased 
Col1A1 mRNA levels (Figure 6C), and these effects were 
magnified in mice fed the combination diet enriched in 
PA and MA. Moreover, mice fed the PA and MA-enriched 
diet showed increased expression of inflammatory 
Figure 5: Effect of myriocin on total hepatic ceramide levels and ER stress. PMH were incubated with PA with or without MA 
(0.5mM) each for 6 hours in the presence of myriocin (20µM) and processed for total ceramide determination by HPLC A. Alternatively, 
expression of CHOP B. and sXBP-1 C. was examined by RT-PCR with or without myriocin. Results are the mean±SEM of N = 5-7 
individual experiments. *p < 0.05 vs. control and PA-treated PMH.
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Figure 6: Chronic consumption of diets enriched in PA plus MA leads to lipodystrophy and progressive liver disease 
and effect of myriocin therapy. Mice were fed diets enriched in PA, MA or PA plus MA (PM) for 6 months with or without myriocin 
treatment in the last 4 months (PM+Myr). Effect on body weigh, liver/body weight, spleen weight and adipose tissue weight were recorded 
at the end of the study A. Serum transaminases levels were determined and liver processed for H&E analyses B. at the end of 6 months. 
Liver sections were staining for Sirius red to determine collagen deposition and expression of Col1α1 was determined by RT-PCR C. 
Inflammatory cytokine expression IL-1β, IL-6 and TNFα was examined in liver samples from mice fed PA, MA or PA plus MA (PM). Liver 
sections from mice were processed for oil-red staining E. Results are the mean±SEM of N = 8-10 individual mice. *p < 0.05 vs. control 
and PA-treated PMH.
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cytokines IL-1β, IL-6 and TNF compared to mice fed diet 
enriched in PA (Figure 6D). These findings suggest that 
the consumption of diets enriched in PA and MA cause 
lipodystrophy, liver injury, inflammation and fibrosis.
Mice fed PA plus MA-enriched diet exhibit 
increased liver ceramide content and ER stress
We next analyzed the liver lipid content following 
the consumption of PA plus MA-enriched diet. Mice 
fed diets enriched in PA with or without MA showed 
significant increase in liver cholesterol levels (Figure 
7A), without change in the TG content, in line with 
the mild hepatic steatosis analyzed by Oil-red staining 
(Figure 6E). Moreover, the hepatic content of FFA did not 
increase in mice fed the diets enriched in PA, MA or their 
combination (Figure 7A). However, total hepatic ceramide 
levels significantly increase in mice fed PA-enriched diet 
and this effect was exacerbated by the presence of PA 
plus MA (Figure 7A). This outcome was accompanied by 
increased expression of CerS6 by PA plus MA compared 
to diet enriched in PA alone (Figure 7B) and this specific 
CerS form exhibits preference for 14:0 and 16:0 fatty 
acids. In addition, PA plus MA decreased the expression of 
CerS2 and CerS4, which are responsible for the synthesis 
of C22-C24 and C20 ceramide species, respectively. 
Gene expression analyses of enzymes involved in lipid 
metabolism indicated increased expression of the catalytic 
subunit of SPT, Sptlc2, and sphingomyelin synthase 
Sgms1 by diets enriched in PA with or without MA 
(Figure 7C). In addition, Hmgcr and Srebf2 involved in 
cholesterol synthesis increased in PA and PA plus MA-
fed mice (Figure 7C). Moreover, fatty acid transporter 
Cd36 expression increased significantly in mice fed PA 
and PA plus MA diet (Figure 7C). Interestingly, mice fed 
PA plus MA-enriched diet exhibited reduced expression of 
Scd1, and Srebf1, which are involved in FFA synthesis and 
esterification. These data indicate that hepatic fatty acids 
are preferentially channeled for ceramide synthesis rather 
than TG formation. Consistent with in vitro findings, PA-
enriched diet induced a marked elevation in ER stress 
markers, which further increased by the combination of 
PA plus MA (Figure 7D). 
In line with findings in PMH, treatment of mice 
with myriocin prevented PA plus MA-induced ceramide 
generation and cholesterol content (Figure 7A), resulting 
in lower liver damage determined by decreased serum 
ALT levels and H&E analyses (Figure 6B), as well as 
attenuation of fibrosis reflected by Sirius Red staining 
and decreased Col1A1 mRNA levels (Figure 6C) and 
decreased expression of inflammation markers (Figure 6 
D). Overall, these findings further support the contribution 
of de novo ceramide synthesis in progressive liver disease 
caused by feeding diets enriched in PA plus MA. 
DISCUSSION
PA is one of the most abundant saturated fatty 
acids present in western diets, which is known to cause 
lipotoxicity by multifaceted mechanisms, including 
mitochondrial dysfunction, lysosomal destabilization and 
ER stress [4-7]. Here we describe for the first time the 
potentiation of PA-induced lipoapoptosis by MA, another 
SFA, which unlike PA is not lipotoxic. As MA is highly 
enriched in milk fat and, particularly, in copra/palmist oils, 
we exposed hepatocytes to a concentration range of MA 
mimicking that found in these foods and derivatives. While 
the onset of ER stress and the recruitment of mitochondrial 
apoptotic pathway induced by PA are potentiated by MA, 
in line with previous observations with PA alone [6, 7], we 
focused on the contribution of ceramide synthesis as this 
particular aspect has not been examined in the presence 
of PA and MA. The role of ceramide in PA-induced ER 
stress and lipotoxicity remains poorly characterized has 
been examined mainly in liver cancer cells and CHO cells 
[31, 32]. 
PA fuels de novo ceramide synthesis by generating 
the d18:1 carbon backbone sphinganine from the 
reduction of 3-ketosphinganine, which is formed by the 
condensation of palmitoyl-CoA with serine in a reaction 
catalyzed by SPT; the subsequent acylation of sphinganine 
with fatty acyl chains of varying lengths generates 
different ceramide species. Hence, PA not only supports 
d18:1 sphinganine formation but is the substrate of CerS6, 
which catalyzes the acylation of sphinganine with PA to 
generate ceramide 16:0 [13, 14]. In the presence of PA 
plus MA, two major changes in ceramide homeostasis are 
observed. First, MA promotes ceramide synthesis from 
PA and kinetically sustains higher total ceramide levels. 
In addition, MA competes with PA for the acylation of 
d18:1 sphinganine, resulting in decreased ceramide 16:0 
and higher ceramide 14:0 level, leading to equimolar 
ceramide14:0 and ceramide 16:0 generation. In line with 
the reported activation of DES upon its myristoylation at 
the N-terminus [21], we observed increased stimulation 
of DES activity using NBD-dehydroceramide 12:0 
as substrate, accounting for the sustained increase in 
total ceramide levels over time. The relative modest 
generation of ceramide 14:0 by MA alone could be due 
to the limitation of endogenous PA levels to support d18:1 
sphinganine generation to be acylated with MA. Although 
MA can also act as a substrate for SPT to generate 
d16:0 sphingolipids, this process is limited by the lower 
affinity of the SPT complex for MA compared to that 
of PA [12, 18, 32, 33]. The expression of the catalytic 
subunit STPLC3 broadens the substrate specificity of 
SPT allowing utilization of myristoyl-CoA for synthesis 
of d16:0 carbon backbone [34]. However, expression 
of SPTLC3 subunit is barely detectable in normal liver, 
although its levels increase in hepatocellular carcinoma 
[35]. 
Oncotarget41490www.impactjournals.com/oncotarget
Figure 7: Feeding diets enriched in PA with or without MA increased hepatic ceramide and cholesterol levels and 
induce ER stress. Mice were fed diet enriched in PA with or without MA for 6 months as in Figure 6 and liver samples were processed 
for hepatic lipid content, ceramide, cholesterol, TG and FFA A. In some cases, mice were treated with myriocin (Myr) in vivo (i.p. 25mg/kg 
daily) for the last 4 months of feeding. Expression of hepatic CerS mRNA from mice fed PA, MA or PA plus MA (PM) B. Gene expression 
of enzymes involved in lipid metabolism and ceramide synthesis C. Western blot of ER stress markers from mice fed PA, MA or PA plus 
MA D. Results are the mean±SEM of N = 8-10 individual mice. *p < 0.05 vs. control and PA-treated PMH.
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Figure 8: Schematic proposal of the molecular events involved in the lipotoxic effects of PA and the potentiation by 
MA. PA fuels ceramide synthesis by providing sphinganine in a reaction catalyzed by SPT. MA in turn potentiates ceramide generation by 
stimulating the activity of DES, and therefore the combination of MA plus PA results in kinetically sustained de novo ceramide production. 
This event is upstream of the induction of ER stress, which in turn recruits the mitochondrial apoptosis program eliciting ROS generation 
and caspase activation, leading to hepatocyte apoptosis. On the hand right side, we show the different specific inhibitors used to interrupt 
this signaling cascade. In addition to ceramide generation, PA is also known to activate other cellular events, including lysosomal membrane 
permeabilization (LMP) and activation of death receptor 5 (DR5), which then contribute to PA-induced lipoapoptosis. While myriocin 
blocks the central events shown (blue rectangle) it is not expected to interfere with LMP and DR5 activation. Further work is required to 
examine the involvement of ceramide synthesis in the recruitment and activation of LMP and DR5 by saturated fatty acids.
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The switch in ceramide profile by PA vs PA plus 
MA resulting in increased ceramide 14:0 and decreased 
ceramide 16:0 is of relevance in the lipotoxicity of PMH. 
Interestingly, PMH are more sensitive to equimolar 
ceramide 14:0 and ceramide 16:0, mimicking the profile 
elicited by PA plus MA, than to either ceramide species 
alone. This increased susceptibility may reflect an 
emerging prosurvival role of ceramide 16:0, which has 
been recently described in cancer cells by regulating 
ER stress response [36]. While MA is not hepatotoxic 
by itself, it has been recently reported that myristate is 
cardiotoxic and induced cardiomyocyte hypertrophy in an 
autophagy-dependent manner [22]. Further investigation 
will be required to decipher the tissue specific cytotoxic 
potential of MA and whether it is related to differential 
ceramide species generation.
The potentiation of PA-induced lipoapoptosis by 
MA involves ER stress and mitochondrial recruitment 
by a mechanism dependent of mitochondrial Ca2+ import 
sensitive to RR. Moreover, antioxidant BHA and caspase 
blockade protect against PA plus MA-mediated cell 
death. Inhibition of ER stress by TUDCA protects against 
PA and MA-induced cell death but does not abrogate 
ceramide synthesis. Furthermore myriocin, a specific 
SPT inhibitor, protects against PA plus MA-induced 
ceramide generation and subsequent ER stress induction 
and hepatocyte apoptosis. Overall, these findings, indicate 
that PA plus MA-induced ceramide generation is upstream 
of ER stress and mitochondrial recruitment. While 
these findings suggest a de novo ceramide synthesis-
ER stress-mitochondria axis contributing to PA-induced 
lipoapoptosis with potentiation by MA, protection with 
myriocin or TUCDA is partial, indicating the participation 
of other pathways independent of de novo ceramide 
synthesis and ER stress. In this regard, PA has been 
shown to elicit hepatocyte apoptosis through lysosomal 
membrane permeabilization [3, 37] or DR5 activation 
[8,9], which could account for the partial protection 
afforded by myriocin. In addition, a direct effect of 
ceramide in mitochondria causing ROS and apoptosis has 
been reported in different cell tpes [13, 38-40], which may 
underlie the residual cell death in the presence of TUDCA. 
Further work will be required to examine the contribution 
of ceramide in PA-induced lysosomal membrane 
permeabilization and DR5 activation (Figure 8).
The role of ceramide in PA-induced lipotoxicity and 
ER stress is controversial. For instance, Listenberger et 
al. claimed that PA-induced cell death in CHO cells did 
not depend on ceramide synthesis [31]. However, the 
inhibition of SPT and CerS inhibition with L-cycloserine 
and fumonisin B1, respectively, decreased caspase-3 
activity and reduced DNA degradation. Moreover, Wei 
et al. discarded the contribution of de novo synthesized 
ceramide in PA-induced lipotoxicity in the H4IIE hepatic 
cell line treated with fumonisin B1 [32]. As expected, 
fumonisin B1 resulted in increased dihydrophingosine 
generation by PA, which has been shown to mediate the 
toxicity of fumonisin B1 in different cell types [41, 42]. 
In addition to these possibilities, the difference between 
tumor cell lines and primary hepatocytes could also 
contribute to the final outcome.
To explore the relevance of the findings in PMH, we 
fed mice diets enriched in PA with or without MA. In line 
with the in vitro observations, the chronic consumption of 
these diets, mimicking the ingestion of copra/palmist oils 
and western foods, resulted in increased liver ceramide 
content and ER stress, effects that were exacerbated 
by the combination PA plus MA, and this outcome was 
accompanied by lipodystrophy, enhanced liver injury, 
inflammation and fibrosis. Consistent with the findings 
in PMH, there was negligible macrovesicular steatosis 
indicating that dietary PA and MA were diverted from TG 
synthesis and preferentially converted in ceramide species. 
This outcome mirrored the increased expression of the 
catalytic subunit of the SPT complex SPTLC2 and CerS6, 
which exhibit preferential affinity for MA and PA, as well 
as the downregulation of SREBP-1 and SCD-1. Besides 
ceramide accumulation, PA plus MA diet also increased 
liver cholesterol levels, which may be consequence of 
ceramide-induced ER stress and subsequent activation 
of the transcription factor SREBP-2 and the enzyme 
catalyzing the rate-limited step in cholesterol synthesis, 
HMGCoAR. Thus, despite absence of macrosteatosis and 
TG deposition, nutritional intake of PA plus MA resulted 
in the selective accumulation of ceramide and cholesterol 
that may account for the observed hepatomegaly. Another 
key feature of this feeding regimen was the marked loss 
of adipose tissue, underlying the nutritional lipodystrophy 
induction by PA plus MA, which contrasts with the 
outcome described with high fat diets typically used for 
obesity and glucose homeostasis studies, suggesting that 
the nutritional fat was diverted to the liver for conversion 
into ceramide. Interestingly, our findings are similar to 
those reported recently in mice fed an atherogenic diet 
enriched in cholesterol (1.25%) with the loss of adipose 
tissue, accumulation of liver cholesterol, inflammation, 
fibrosis and liver injury [43].
These in vivo findings may have important 
implications. While most studies investigating the 
effects of SFA have focused in coronary heart disease 
and atherosclerosis [44], our results imply that people 
consuming diets enriched in PA and MA may develop 
lipodystrophy and chronic liver disease, characterized 
by the lack of TG accumulation and macrovesicular 
steatosis and the preferential accumulation of ceramide 
and cholesterol levels, contributing to hepatomegaly 
and liver injury. Moreover, unlike other high fat diets 
consumption of diets enriched in PA plus MA does not 
result in increased body weight although it induces 
inflammation and fibrosis indicative of progressive 
NAFLD. Interestingly, recent studies have reported that 
children of Asian origin exhibit similar abnormal liver 
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function tests but increased prevalence of moderate to 
severe fibrosis compared to Caucasians despite decreased 
body mass index [45]. Further investigation is needed 
to ascertain whether differential nutritional intake and 
consumption of PA plus MA in this children population 
can account for this outcome.
MATERIALS AND METHODS
Mice, hepatocyte isolation and treatments
Wild type mice (C57BL/6J, Charles River 
Laboratories, Wilmington, MA) and CerS2+/- mice 
(obtained from Drs. A. Futerman and S. Summers) were 
used as the source of PMH and were isolated as previously 
described [46]. PMH were treated with PA, MA or OA 
alone or in combination at equimolar concentrations 
(0.25-1mM) for 1-12 hours. Stock solutions of PA, 
MA or OA were prepared as described [6] and the final 
working concentrations were made with 0.5-1% (w/v) 
fatty acid free bovine serum albumin (BSA, Roche). 
FFA:BSA ratio ranged from 3:1 to 6:1 depending on 
the final FFA concentration. High FFA:BSA ratio has 
been observed in states of insulin resistance and obesity, 
two risk factors for NASH [47]. In some cases, PMH 
were treated with butylated hydroxyanisole (BHA, 
50 - 200 µM) (Sigma-Aldrich) in absolute ethanol, 
z-VAD-FMK (5 - 15 µM) (Abcam, Cambridge, UK) in 
dimethyl sulfoxide (DMSO), myriocin (20 µM) (Enzo 
Life Sciences, Farmingdale, NY) in NaOH (50 mM) and 
DMSO (0.1%), tauroursodeoxycholic acid (TUDCA, 25 
µM) (Calbiochem, Billerica, MA), ruthenium red (RR, 10 
µM) and the JNK inhibitor SP600125 (20µΜ). Cell death, 
lipodomic analyses, total ceramide levels, DES activity 
from NBD-dihydroceramide C12; ROS generation and 
determination of ER stress are described in Supplemental 
Material section.
Ceramide analysis by HPLC
Cellular ceramide levels were determined by 
high performance liquid chromatography (HPLC) after 
derivatization of the sphingoid base with O-phthaldehyde 
following deacylation of ceramide, as described 
previously [46]. Briefly, cells were collected in PBS 
and lipids were extracted with methanol:chloroform 
(1:2, v/v) isolation. The organic phase was resuspended 
in 250 µL of 1 N KOH in methanol, and incubated 1 
hour at 100°C, yielding free sphingoid base, followed 
by derivatization with O-phthaldehyde. Samples were 
centrifuged and analyzed by HPLC in a reverse phase C18 
column (Teknokroma) using a Gilson fluorimetric detector 
(Middleton, WI) with an excitation wavelength of 252 nm 
and an emission wavelength of 483 nm. The mobile phase 
for the gradient system was 5 mM potassium phosphate 
buffer (pH = 6.5):methanol (85:15, v/v) for mobile phase 
A and acetonitrile:methanol (75:25, v/v) for mobile 
phase B and the flow rate was 1 mL/min. The gradient 
program was 0-1 min 52.94 A, 47.06 B; 1-6 min 52.94-
5.88 A, 47.06-94.11 B; 6-21min 5.88 A, 94.11 B; 21-25 
min 5.88-52.94 A, 94.11-47.06 B, 25-30 min 52.94 A, 
47.06 B. Quantification of ceramide peak was calculated 
according to a calibration curve derived from commercial 
purified standards and values were normalized by protein 
quantification.
Ceramide species analysis with mass spectrometry
Lipids from homogenate samples were extracted 
with methanol:chloroform isolation (1:2, v/v). Mass 
spectrometry analysis of lipid species was performed in 
the Research Unit on Bioactive Molecules at the Institute 
of Advanced Chemistry of Catalonia (IQAC). Cells or 
tissue homogenates were pelleted, washed in PBS, and 
transferred to glass vials. Sphingolipid extracts were 
spiked with internal standards (N-dodecanoylsphingosine, 
N-dodecanoylglucosylsphingosine, and 
N-dodecanoylsphingosylphosphorylcholine, 0.2nmol 
each) and analysed in a Waters Aquity UPLC system 
connected to a Waters LCT Premier orthogonal accelerated 
time of flight mass spectrometer (Waters, Millford, MA) 
operated in positive electrospray ionisation mode. The 
analytical column was a 100mm x 2.1mm i.d., 1.7μm C8 
Acquity UPLC BEH (Waters). The two mobile phases 
were phase A: water/formic acid (500/1 v/v); phase B: 
methanol/formic acid (500/1 v/v), both also contained 
5mM ammonium formate. A linear gradient was 
programmed— 0.0min: 80% B; 3min: 90% B; 6min: 90% 
B; 15min: 99% B; 18min: 99% B; 20min: 80% B. The 
flow rate was 0.3mL/min. The column was maintained at 
30°C. Quantification was carried out using the extracted 
ion chromatogram of each compound, using 50mDa 
windows. The linear dynamic range was determined by 
injecting standard mixtures.
Determination of dihydroceramide desaturase 
and serine palmitoyltransferase activities
The determination of DES activity was performed 
as described in detail previously [21]. Briefly, cell extracts 
were incubated with NBD-dihydroceramide C12:0 and the 
resulting synthesized ceramide 12:0 was resolved from 
the precursor dihydroceramide by HPTLC as described 
previously [21]. SPT activity was determined as described 
previously [24], based on the conversion of water-
soluble [3H]serine to the chloroform-soluble product, 
3-ketodihydrosphingosine.
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In vivo experiments
Studies were conducted in accordance with the 
principles and procedures outlined in the National 
Institutes of Health (NIH) Guide for the Care and Use of 
Laboratory Animals and were approved by the institutional 
animal care committee of the Universitat de Barcelona. 
Eight weeks old male mice (C57BL/6J, Charles River 
Laboratories) were fed custom-made fat diets ad libitum 
(Research Diets, New Brunswick, NJ), enriched in PA 
(30% of Kcal), MA (30% of Kcal) or their combination 
(PM) as the lipid source, complemented with the presence 
of essential the fatty acid C18:3 n-3 [19] for 6 months. In 
some cases, mice fed the PA plus MA enriched diet were 
treated with myriocin (i.p. 25mg/kg dayly) for the last 
4 months of feeding to examine the impact of blocking 
ceramide synthesis in liver disease.
Statistical analysis
Results are expressed as mean ± standard error of 
the mean (SEM). Statistical significance of mean values 
has been assessed using Student T-test and one or two-way 
ANOVA. Statistics were performed using GraphPad Prism 
6 software.
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